• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by IDEAYA Biosciences Inc. (Amendment)

    2/13/24 7:31:29 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IDYA alert in real time by email
    SC 13G/A 1 idya13ga.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. 2)

    IDEAYA Biosciences, Inc.

    (Name of Issuer)

    Common Stock, $0.0001 par value

    (Title of Class of Securities)

    45166A102

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X]       Rule 13d-1(b)

    [X]       Rule 13d-1(c)

    [ ]       Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     1 
    CUSIP No. 45166A102

     

     

    1.Names of Reporting Persons.

    Logos Global Management LP

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)

    (b) X

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 1,800,000
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 1,800,000

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 1,800,000

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 2.8%

     

    12.Type of Reporting Person (See Instructions) IA, PN

     2 
    CUSIP No. 45166A102

     

     

    1.Names of Reporting Persons.

    Logos Global Management GP LLC

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)

    (b) X

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 1,800,000
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 1,800,000

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 1,800,000

    a

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 2.8%

     

    12.Type of Reporting Person (See Instructions) HC, OO

     

     3 
    CUSIP No. 45166A102

     

     

    1.Names of Reporting Persons.

    Arsani William

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)

    (b) X

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization United States

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 1,800,000
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 1,800,000

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 1,800,000

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 2.8%

     

    12.Type of Reporting Person (See Instructions) HC, IN

     

     4 
    CUSIP No. 45166A102

     

     

    1.Names of Reporting Persons.

    Logos Global Master Fund LP

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) ___X__

     

    3. SEC Use Only

     

     

    4.Citizenship or Place of Organization Cayman Islands

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 1,800,000
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 1,800,000

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 1,800,000

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 2.8%

     

    12.Type of Reporting Person (See Instructions) PN

     

     

     5 
    CUSIP No. 45166A102

     

     

    1.Names of Reporting Persons.

    Logos GP LLC

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)

    (b) X

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 1,800,000
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 1,800,000

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 1,800,000

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 2.8%

     

    12.Type of Reporting Person (See Instructions) OO

     

     6 
    CUSIP No. 45166A102

     

     

    Item1.
    (a)Name of Issuer

    IDEAYA Biosciences, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

    7000 Shoreline Court, Suite 350, South San Francisco, CA 94080

    ________________________________________________________________________

    Item2.
    (a)The names of the persons filing this statement are:

    Logos Global Master Fund LP (“Global Fund”), Logos Global Management LP (“Logos Global”), Logos GP LLC (“Logos GP”), Logos Global Management GP LLC (“Logos Global GP”), and Arsani William (collectively, the “Filers”).

     

    Logos Global is the investment adviser to investment funds, including Global Fund. Logos Global GP is the general partner of Logos Global. Dr. William is a control person of Logos Global and Logos Global GP.

     

    The Filers are filing this statement jointly but not as members of a group, and they expressly disclaim membership in a group. In addition, filing this Schedule 13G on behalf of Global Fund should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    Each Filer also disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein.

     

    (b)The principal business office of the Filers is located at:

    One Letterman Drive, Building D, Suite D3-700, San Francisco, California 94129

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s shares of Common Stock, $0.0001 par value (the “Stock”).

     

    (e)The CUSIP number of the Issuer is: 45166A102.
     7 
    CUSIP No. 45166A102

     

    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)[ X ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E) as to Logos Global.
    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).
    (g)[ X ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G)
    as to Logos Global GP and Dr. William.
    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
    (j)[ ] Group, in accordance with section 240.13d-1(b)(1)(ii)(J).
    Item 4.Ownership.

    See Items 5-9 and 11 of the cover page for each Filer.

    The percentages reported in this Schedule 13G are based on 64,459,472 shares of Common Stock outstanding as of November 3, 2023, as reported in the Issuer’s Form 10-Q filed on November 7, 2023.

    Item 5.Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ X ].

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

    Item 8.Identification and Classification of Members of the Group.

    Not applicable.

     

     

    Item 9.Notice of Dissolution of Group.

    Not applicable.

    Item 10.Certification.

    Certification of Logos Global, Logos Global GP and Dr. William:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Certification of Global Fund and Logos GP:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     8 
    CUSIP No. 45166A102

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February __, 2024

     

     

     

    /s/ Arsani William
    Arsani William

     

     
    Logos Global Management LP


    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Partner

    Logos Global Master Fund LP

     

    By Logos Global Management LP, its investment manager and attorney-in-fact

     

    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Partner

     

    Logos Global Management GP LLC


    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Member

     

    Logos GP LLC


    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Member

     

     9 
    CUSIP No. 45166A102

    EXHIBIT A

    AGREEMENT REGARDING JOINT FILING
    OF STATEMENT ON SCHEDULE 13D OR 13G

    The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D, Schedule 13G or forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Logos Global Management LP, a Delaware limited partnership, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Act, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

    Dated: February 13, 2024

     

     

    /s/ Arsani William
    Arsani William

     

     
    Logos Global Management LP


    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Partner

    Logos Global Master Fund LP

     

    By Logos Global Management LP, its investment manager and attorney-in-fact

     

    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Partner

     

    Logos Global Management GP LLC


    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Member

     

    Logos GP LLC


    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Member

     

     

    Get the next $IDYA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IDYA

    DatePrice TargetRatingAnalyst
    11/18/2024$51.00Overweight
    Stephens
    11/5/2024$27.00Outperform → Market Perform
    Leerink Partners
    10/24/2024$50.00Buy
    UBS
    10/15/2024Overweight
    Cantor Fitzgerald
    7/8/2024$50.00Outperform
    Mizuho
    3/8/2024$55.00Buy
    BTIG Research
    8/8/2023$33.00Outperform
    SVB Securities
    5/24/2023$32.00Buy
    Goldman
    More analyst ratings

    $IDYA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

      ~$1.05 billion of cash, cash equivalents and marketable securities as of March 31, 2025, and an updated cash runway guidance into 2029; commercial readiness activities ongoingOver 300 patients enrolled in darovasertib and crizotinib registrational 1L HLA-A2-negative MUM trial; targeting median PFS results by YE 2025 to enable potential accelerated approval filingSuccessful FDA Type D meeting completed to finalize darovasertib Ph3 registrational trial design and received U.S. FDA Breakthrough Therapy Designation in neoadjuvant UMTargeting three darovasertib program clinical data updates at medical conferences in 2025, including 1L MUM mOS results in >40 patients and neoadjuvant UM data in >90

      5/6/25 6:05:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors

      Targeting to evaluate IDE849 (SHR-4849) in SCLC, NETs, and other DLL3-upregulated solid tumors, and in combination with IDE161/PARG to potentially enhance durabilityTargeting to present clinical data of over 40 SCLC patients, including the dose escalation and expansion, from partner Hengrui at medical conference in Q3 2025SOUTH SAN FRANCISCO, Calif., May 6, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial to

      5/6/25 6:00:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events

      SOUTH SAN FRANCISCO, Calif., April 28, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events. Barclays Hosted: Peter Lawson's Catalyst & Key Debate Calls & Investor 1x1'sThursday, May 8th, 2025 at 11:00 AM ET Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Peter Lawson, D.Phil., Managing Director, Equity Research Analyst2025 RBC Capital Markets Global Healthcar

      4/28/25 6:00:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IDYA
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by IDEAYA Biosciences Inc.

      SCHEDULE 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)

      5/14/25 12:26:18 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by IDEAYA Biosciences Inc.

      10-Q - IDEAYA Biosciences, Inc. (0001676725) (Filer)

      5/6/25 4:05:35 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer)

      5/6/25 6:05:15 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IDYA
    Leadership Updates

    Live Leadership Updates

    See more
    • IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer

      SOUTH SAN FRANCISCO, Calif., Feb. 10, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the appointment of Joshua Bleharski, Ph.D. as Chief Financial Officer.  Dr. Bleharski joins IDEAYA from J.P. Morgan, where he spent nearly 17 years advising clients in the biopharma sector on capital markets transactions, corporate strategy and other investment banking services. IDEAYA anticipates that Dr. Bleharski will complete the transition into his new role by early May. 

      2/10/25 6:00:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer

      Brings over 20-year global commercialization experience in oncology with leading biopharmaceutical companies Gilead Sciences and Bristol Myers Squibb, including leadership of multiple commercial launches for products including Trodelvy® and Opdivo®SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the appointment of Stu Dorman as Chief Commercial Officer. Mr. Dorman has a track record of commercial success in numerous specialty disease areas with over 20 years of oncology and hematology experience.

      11/18/24 6:00:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel

      Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the U.S. FDASOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that Douglas B. Snyder, joined the company as its Senior Vice President, General Counsel on September 18, 2024. "Doug brings a broad legal background in the healthcare field spanning biotechnology, pharm

      9/18/24 6:00:00 AM ET
      $IDYA
      $GWPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals

    $IDYA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Medical Officer Beaupre Darrin

      4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)

      2/28/25 6:03:47 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Commercial Officer Dorman Stuart

      4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)

      2/28/25 6:02:27 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Ruiz Briseno Andres

      4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)

      2/28/25 6:02:04 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IDYA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by IDEAYA Biosciences Inc.

      SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)

      11/14/24 4:23:02 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by IDEAYA Biosciences Inc.

      SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)

      11/14/24 3:13:37 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by IDEAYA Biosciences Inc.

      SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)

      11/14/24 1:22:38 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IDYA
    Financials

    Live finance-specific insights

    See more
    • IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma

      Phase 2 company-sponsored and IST neoadjuvant uveal melanoma (UM) clinical data update in 49 evaluable patients, demonstrates ~49% of patients with >30% tumor shrinkage by product of diameters, and ~61% eye preservation rate for enucleation patientsTargeting to initiate Phase 3 randomized registrational trial in neoadjuvant UM following finalization of the clinical protocol with FDAClinical endpoints supportive of full approval based on FDA guidance: Eye preservation rate as the primary endpoint for enucleation patients. Time to vision loss as the primary endpoint for plaque brachytherapy patients. No detriment to Event-Free-Survival (EFS) in the treatment arms is a secondary endpointDiscuss

      9/23/24 6:00:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024

      SOUTH SAN FRANCISCO, Calif., Sept. 22, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that the company plans to issue a pre-market press release and conduct an investor webcast on Monday, September 23, 2024, at 8:00 a.m. ET to report interim Phase 2 data for darovasertib and provide a regulatory update from FDA Type C meeting in neoadjuvant uveal melanoma (UM). Darovasertib is a potent and selective protein kinase C (PKC) inhibitor being developed to broadly address primary and metastatic UM.

      9/22/24 9:00:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer

      ~39% Overall Response Rate (ORR): 1 CR and 6 PRs (2 awaiting confirmation) by RECIST 1.1 out of 18 evaluable MTAP-deletion urothelial and NSCLC patients~94% Disease Control Rate (DCR): 1 CR and 6 PRs and 10 SD by RECIST 1.1~78% of Patients with Tumor Shrinkage: 14 patients observed tumor shrinkage~81% ctDNA Molecular Response Rate (MRR): 13 of 16 patients with > 50% ctDNA reductionAE Profile: ~5.6% drug-related grade >3 AEs and no drug-related SAEs or discontinuations at 30 mg once-a-day expansion doseIDE397 expansion dose of 30 mg once-a-day achieved target drug coverage and plasma SAM pharmacodynamic reduction associated with preclinical tumor regressions~48k U.S. annual incidence of MTAP-

      7/8/24 6:00:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IDYA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stephens initiated coverage on IDEAYA Biosciences with a new price target

      Stephens initiated coverage of IDEAYA Biosciences with a rating of Overweight and set a new price target of $51.00

      11/18/24 8:39:33 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Biosciences downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded IDEAYA Biosciences from Outperform to Market Perform and set a new price target of $27.00

      11/5/24 7:22:44 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on IDEAYA Biosciences with a new price target

      UBS initiated coverage of IDEAYA Biosciences with a rating of Buy and set a new price target of $50.00

      10/24/24 6:22:17 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care